LIQUIDITY AND MANAGEMENT'S PLAN	12 Months Ended
Sep. 30, 2019
LIQUIDITY AND MANAGEMENT'S PLAN
LIQUIDITY AND MANAGEMENT'S PLAN	NOTE A – LIQUIDITY AND MANAGEMENT’S PLAN Applied DNA Sciences, Inc. (the “Company”) has recurring net losses, which have resulted in an accumulated deficit of $256,805,589 as of September 30, 2019. The Company incurred a net loss of $8,632,446 and generated negative operating cash flow of $6,861,772 for the fiscal year ended September 30, 2019. At September 30, 2019 the Company had cash and cash equivalents of $558,988 and working capital deficit of $99,682. The Company’s current capital resources include cash and cash equivalents, accounts receivable and inventories. The Company expects to finance its operations primarily through cash received from the November 2019 underwritten public offering, discussed below, as well as collection of its accounts receivable. The Company estimates that it will have sufficient cash and cash equivalents to fund operations for the next twelve months from the date of filing of this annual report. Historically, the Company has financed its operations principally from the sale of equity and equity-linked securities. As discussed in Note H, on November 15, 2019 the Company closed on an underwritten public offering of 2,285,000 shares of common stock and warrants to purchase up to an aggregate of 2,285,000 shares of common stock. Each share of common stock was sold together with one warrant to purchase one share of common stock at a combined effective price to the public of $5.25 per share and accompanying warrant. Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, were approximately $12.0 million. After deducting underwriting discounts and commissions and other estimated offering expenses total expected net proceeds are $10.8 million. The Company has granted the underwriters a 45-day option to purchase up to an additional 342,750 shares of common stock and/or warrants to purchase up to 342,750 shares of common stock, at the public offering price less discounts and commissions. The Company may require additional funds to complete the continued development of its products, product manufacturing, and to fund expected additional losses from operations until revenues are sufficient to cover its operating expenses. If revenues are not sufficient to cover the Company's operating expenses, and if it is not successful in obtaining the necessary additional financing, the Company will most likely be forced to reduce operations.

NOTE A – LIQUIDITY AND MANAGEMENT’S PLAN

Applied DNA Sciences, Inc. (the “Company”) has recurring net losses, which have resulted in an accumulated deficit of $256,805,589 as of September 30, 2019. The Company incurred a net loss of $8,632,446 and generated negative operating cash flow of $6,861,772 for the fiscal year ended September 30, 2019. At September 30, 2019 the Company had cash and cash equivalents of $558,988 and working capital deficit of $99,682.

The Company’s current capital resources include cash and cash equivalents, accounts receivable and inventories. The Company expects to finance its operations primarily through cash received from the November 2019 underwritten public offering, discussed below, as well as collection of its accounts receivable. The Company estimates that it will have sufficient cash and cash equivalents to fund operations for the next twelve months from the date of filing of this annual report. Historically, the Company has financed its operations principally from the sale of equity and equity-linked securities.

As discussed in Note H, on November 15, 2019 the Company closed on an underwritten public offering of 2,285,000 shares of common stock and warrants to purchase up to an aggregate of 2,285,000 shares of common stock. Each share of common stock was sold together with one warrant to purchase one share of common stock at a combined effective price to the public of $5.25 per share and accompanying warrant. Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, were approximately $12.0 million. After deducting underwriting discounts and commissions and other estimated offering expenses total expected net proceeds are $10.8 million.

The Company has granted the underwriters a 45-day option to purchase up to an additional 342,750 shares of common stock and/or warrants to purchase up to 342,750 shares of common stock, at the public offering price less discounts and commissions.

The Company may require additional funds to complete the continued development of its products, product manufacturing, and to fund expected additional losses from operations until revenues are sufficient to cover its operating expenses. If revenues are not sufficient to cover the Company's operating expenses, and if it is not successful in obtaining the necessary additional financing, the Company will most likely be forced to reduce operations.